Clinical Trial Update: A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors [Phase 2]

View source ↗

Summary

This Phase II trial in children with refractory solid tumors compares carboplatin plus irinotecan to irinotecan alone and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Neoplasms | Phase 2 | Status: COMPLETED